11th Feb 2015 12:18
LONDON (Alliance News) - Immupharma PLC said Wednesday that a phase I/IIa clinical trial of its cancer programme IPP-204106 met its primary objective, and it will now commence a phase II study in pancreatic cancer.
The phase I/IIa trial was a dose-finding adaptive study, and the results showed that the maximum tolerated dose with chondroitin sulfate was 9 milligrams per kilogram.
In preclinical studies it was shown that a 1 milligram per kilogram equivalent human does with chondroitin sulfate in a combination therapy using the cancer drug Gemcitabin demonstrated a massive reduction in tumour volume in mouse pancreatic cancer, Immupharma said.
Shares in Immupharma are trading down 1.7% at 53.60 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma